Bruce Keyt
CIK 1787362 · CHIEF SCIENTIFIC OFFICER · last filed 2024-09-17
Bruce Keyt is a CHIEF SCIENTIFIC OFFICER who has filed 51 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for IGMS, was dated Dec 16, 2024. Across all open-market trades the lifetime net is −$3.6M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IGMS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MOUNTAIN VIEW, CA 94043
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IGM Biosciences, Inc. (IGMS) Delisted | CHIEF SCIENTIFIC OFFICER | 246,987 | $1.27 | $313.7K | -$3.64M | 49 | 2024-09-17 |
Recent Filings
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-16 | IGM Biosciences, Inc. (IGMS) Delisted | Notice (144) | −18,762 | -$134.5K | EDGAR |
| 2024-09-17 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −1,487 | -$17.2K | EDGAR |
| 2024-07-23 | IGM Biosciences, Inc. (IGMS) Delisted | Mixed | +46,666 | $0 | EDGAR |
| 2024-06-18 | IGM Biosciences, Inc. (IGMS) Delisted | Mixed | +1,894 | $6.7K | EDGAR |
| 2024-03-28 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +24,019 | $0 | EDGAR |
| 2024-03-15 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −3,945 | -$39.5K | EDGAR |
| 2024-03-14 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +46,250 | $0 | EDGAR |
| 2024-03-05 | IGM Biosciences, Inc. (IGMS) Delisted | Exer (M) | +3,026 | $2.8K | EDGAR |
| 2023-12-15 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −7,574 | -$43.8K | EDGAR |
| 2023-12-13 | IGM Biosciences, Inc. (IGMS) Delisted | Notice (144) | −10,567 | -$63.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.